Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

周四 - Cantor Fitzgerald对GH Research PLC (NASDAQ: GHRS )给予"增持"评级，目标价设定为14.00美元。这一新的评级基于GHRS的GH001（一种吸入式5-MeO-DMT疗法）有望成为难治性抑郁症（TRD）标准疗法的潜力。Cantor ...

Cantor Fitzgerald initiated coverage of GH Research (GHRS) with an Overweight rating and $14 price target Maximize Your Portfolio with Data ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

As of September 2024, GH Research had $193 million in cash but expects that by the end of December, the cash will likely be roughly $182 million. The company has an accumulated deficit of $97 million.

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

周一，Rodman & Renshaw的分析师Elemer Piros将GH Research PLC (NASDAQ: GHRS )的12个月目标价从此前的24.00美元上调至42.00美元。在该公司宣布其用于治疗难治性抑郁症 (TRD)的可吸入mebufotenin候选药物GH001的临床试验取得成功后，该机构维持对该股票的买入评级。

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price ...